Chimeric Therapeutics: Funding, Investors & Team (Sep 2026)
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.
Chimeric Therapeutics has raised $2.9M across 1 funding round on record, the most recent an undisclosed round of $2.9M announced in Dec 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Chimeric Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Chimeric Therapeutics Funding Rounds
Chimeric Therapeutics Founders and Leadership Team
Contact details for the Chimeric Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Chimeric Therapeutics Funding Compared to Other Biotechnology Startups
Chimeric Therapeutics' latest round of $2.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Chimeric Therapeutics in Biotechnology and Carlton South
Companies Similar to Chimeric Therapeutics
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Chimeric Therapeutics Funding FAQs
What does Chimeric Therapeutics do?
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.
How much funding has Chimeric Therapeutics raised?
Chimeric Therapeutics has raised $2.9M across 1 round on record. The most recent is an undisclosed round of $2.9M announced in Dec 2025.
When did Chimeric Therapeutics last raise funding?
Chimeric Therapeutics' most recent funding round on record is an undisclosed round of $2.9M, announced in Dec 2025.
Who founded Chimeric Therapeutics?
FundedIQ lists Paul Hopper (Founder) at Chimeric Therapeutics.
Where is Chimeric Therapeutics headquartered?
Chimeric Therapeutics is based in Carlton South, Victoria, Australia.
How many employees does Chimeric Therapeutics have?
Chimeric Therapeutics is in the 1-10 employee band.
How does Chimeric Therapeutics' funding compare to other Biotechnology startups?
Chimeric Therapeutics' latest round of $2.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Chimeric Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Chimeric Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.